Security
Orchestra BioMed Holdings, Inc. Ordinary Shares · OBIO
OBIONASDAQCommon stockCurrentCIK 1814114Updated Oct 3, 2026
Name history
Health Sciences Acquisitions Corp 2 · through Jan 26, 2023
OBIO price & chart
Loading TradingView…
NASDAQ:OBIO on TradingView ↗About the company
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates, Atrioventricular Interval Modulation (AVIM) Therapy and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients …
In the news
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference ↗
Recent filings
4 filing
144 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 114,857,000Source | 76,173,000Source | 95,212,000Source | 68,075,577Source |
| Property, Plant and Equipment, NetUSD | 1,715,000Source | 1,384,000Source | 1,279,000Source | 1,489,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 34,690,000Source | 22,261,000Source | 30,559,000Source | 175,161Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 95,000Source | 92,000Source | 99,000Source | — |
| Inventory, NetUSD | 310,000Source | 173,000Source | 146,000Source | — |
| Assets, CurrentUSD | 107,911,000Source | 69,171,000Source | 89,114,000Source | 299,079Source |
| Prepaid Expense and Other Assets, CurrentUSD | 994,000Source | 2,094,000Source | 1,274,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 1,496,000Source | 2,103,000Source | 1,555,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 51,479,000Source | 43,215,000Source | 27,169,000Source | 7,343,755Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 6,000Source | 4,000Source | 4,000Source | 445Source |
| Additional Paid in CapitalUSD | 416,083,000Source | 342,780,000Source | 316,903,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -362,579,000Source | -309,878,000Source | -248,854,000Source | -6,945,121Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 60,000Source | 52,000Source | -10,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | — | — | — | -6,944,676Source |
| Liabilities and EquityUSD | 114,857,000Source | 76,173,000Source | 95,212,000Source | 68,075,577Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 16,736,000Source | 16,207,000Source | 11,208,000Source | 1,743,755Source |
| Operating Lease, Liability, CurrentUSD | 751,000Source | 550,000Source | 649,000Source | — |
| Accounts Payable, CurrentUSD | 6,095,000Source | 5,134,000Source | 2,900,000Source | 376,930Source |
| Operating Lease, Liability, NoncurrentUSD | 936,000Source | 1,687,000Source | 1,038,000Source | — |
| Deferred Income Tax Liabilities, NetUSD | 393,000Source | 561,000Source | 508,000Source | — |
| Other Liabilities, NoncurrentUSD | 308,000Source | 40,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 9,890,000Source | 6,084,000Source | 5,149,000Source | 1,366,825Source |
| Deferred Revenue, CurrentUSD | — | 4,439,000Source | 2,510,000Source | — |
| Deferred Revenue, NoncurrentUSD | — | 10,989,000Source | 14,923,000Source | — |
| Long-term DebtUSD | 15,000,000Source | 15,000,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -52,701,000Source | -61,024,000Source | -49,120,000Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 327,000Source | 308,000Source | 287,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 11,978,000Source | 10,615,000Source | 7,625,000Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 3,000Source | -22,000Source | 3,000Source | — |
| Increase (Decrease) in InventoriesUSD | 137,000Source | 28,000Source | -131,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | 375,542Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -48,963,000Source | -50,558,000Source | -46,127,000Source | -1,579,299Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -26,941,000Source | 13,089,000Source | 10,687,000Source | 92,591,090Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 489,000Source | 289,000Source | 78,000Source | — |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 1,552,000Source | 550,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 88,333,000Source | 29,171,000Source | 46,215,000Source | -92,591,090Source |
| Repayments of Long-term DebtUSD | — | — | 10,849,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 12,429,000Source | -8,298,000Source | 10,775,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 34,690,000Source | 22,261,000Source | 30,559,000Source | 175,161Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | 215,000Source | 31,000Source | 112,000Source | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | — | — | — |
| DepreciationUSD | 327,000Source | 308,000Source | 287,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | -68,000Source | -18,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -1,151,000Source | — |
| General and Administrative ExpenseUSD | — | — | — | 2,960,264Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Inventory Write-downUSD | 0Source | 0Source | 0Source | — |
| Investment Income, InterestUSD | — | — | — | 345,141Source |
| Marketable Securities, Unrealized Gain (Loss)USD | 8,000Source | 62,000Source | -2,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -52,701,000Source | -61,024,000Source | -49,120,000Source | -2,735,123Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -52,955,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | -11,000Source | — | — |
| Other Operating Income (Expense), NetUSD | -894,000Source | 3,277,000Source | 2,386,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 91,000Source | 240,000Source | 231,000Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | 345,141Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 33,482,000Source | 2,638,000Source | 2,760,000Source | — |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 26,914,000Source | 23,931,000Source | 20,258,000Source | — |
| Operating Income (Loss)USD | -51,807,000Source | -64,301,000Source | -51,506,000Source | -3,080,264Source |
| Other Nonoperating Income (Expense)USD | — | -11,000Source | — | — |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -52,701,000Source | -61,024,000Source | -49,120,000Source | -2,735,123Source |
| Earnings Per Share, BasicUSD per share | -1.11Source | -1.66Source | -1.48Source | -0.17Source |
| Earnings Per Share, DilutedUSD per share | -1.11Source | -1.66Source | -1.48Source | -0.17Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 47,747,078Source | 36,821,042Source | 33,225,227Source | 16,425,826Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 47,747,078Source | 36,821,042Source | 33,225,227Source | 16,425,826Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 85,289,000Source | 66,939,000Source | 54,266,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | -68,000Source | -18,000Source | — |
| General and Administrative ExpenseUSD | — | — | — | 2,960,264Source |
| Interest Expense, DebtUSD | — | 297,000Source | 1,400,000Source | — |
| Interest Income (Expense), NetUSD | — | — | 3,849,000Source | — |
| Interest Income (Expense), Nonoperating, NetUSD | -1,148,000Source | 3,356,000Source | — | — |
| Investment Income, InterestUSD | — | — | — | 345,141Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -52,955,000Source | — | — | — |
| Other ExpensesUSD | — | — | — | 120,000Source |
| Other Operating Income (Expense), NetUSD | -894,000Source | 3,277,000Source | 2,386,000Source | — |
| Research and Development ExpenseUSD | 58,185,000Source | 42,804,000Source | 33,822,000Source | — |
Filing attachments
tm2626728d1_ex99-1.htm · 8-K · 2026-10-01
Exhibit 99.1 Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy 330 patients randomized as of September 30, 2026, surpassing full trial enrollment target Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗tm2624943d1_ex99-1.htm · 8-K · 2026-09-08
EX-99.1 2 tm2624943d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Accelerating high - impact technologies to patients through risk - reward sharing partnerships Corporate Overview | September 2026 Nasdaq : OBIO Forward - Looking Statements This presentation has been prepared for informational purposes only from information supplied by Orchestra BioMed Holdings, Inc., referred to herein as “we,” “our,” “Orchestra BioMed,” and the “Company,” and from third - party sources indicated herein. Such thi…
Read attachment ↗tm262832d1_ex99-1.htm · 8-K · 2026-01-12
EX-99.1 2 tm262832d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics $11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategic holding of Orchestra BioMed since the Company’s formation NEW HOPE, PA, January 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed …
Read attachment ↗tm2531129d1_ex99-1.htm · 8-K · 2025-11-13
EX-99.1 2 tm2531129d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Orchestra BioMed Third Quarter 2025 Corporate Update Conference Call 12 November 2025 C O R P O R A T E P A R T I C I P A N T S Kelsey Kirk-Ellis, Director, Corporate Communications David Hochman, Chairman, Chief Executive Officer and Founder Andrew Taylor, Chief Financial Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Matthew O’Brien, Piper Sandler Matthew Miksic, Barclays Marie Thibault, BTIG Anderson Schoc…
Read attachment ↗tm2531129d1_ex99-2.htm · 8-K · 2025-11-13
EX-99.2 3 tm2531129d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Orchestra BioMed Business Update November 2025 Nasdaq: OBIO Forward - Looking Statements dŚŝƐ ƉƌĞƐĞŶƚĂƚŝŽŶ ŚĂƐ ďĞĞŶ ƉƌĞƉĂƌĞĚ ĨŽƌ ŝŶĨŽƌŵĂƚŝŽŶĂů ƉƵƌƉŽƐĞƐ ŽŶůLJ ĨƌŽŵ ŝŶĨŽƌŵĂƚŝŽŶ ƐƵƉƉůŝĞĚ ďLJ KƌĐŚĞƐƚƌĂ ŝŽDĞĚ,ŽůĚŝŶŐƐ͕ /ŶĐ ͘ ͕ ƌĞĨĞƌƌĞĚ ƚŽ ŚĞƌĞŝŶ ĂƐ ͞ ǁĞ͕ ͟ ͞ ŽƵƌ͕ ͟ ͞ KƌĐŚĞƐƚƌĂ ŝŽDĞĚ͕ ͟ ĂŶĚ ͞ ƚŚĞ ŽŵƉĂŶLJ͕ ͟ ĂŶĚ ĨƌŽŵ ƚŚŝƌĚ Ͳ ƉĂƌƚLJ ƐŽƵƌĐĞƐ ŝŶĚŝĐĂƚĞĚ ŚĞƌĞŝŶ ͘ ^ƵĐŚ ƚŚŝƌĚ Ͳ ƉĂƌƚLJ ŝŶĨŽƌŵĂƚŝŽŶ ŚĂƐ ŶŽƚ ďĞĞŶ ŝŶĚĞƉĞŶĚĞŶƚůLJ ǀĞƌŝĨŝĞĚ ͘ KƌĐŚĞƐƚƌĂ ŝŽDĞĚ ŵ…
Read attachment ↗tm2529796d1_ex99-1.htm · 8-K · 2025-10-30
EX-99.1 2 tm2529796d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Orchestra BioMed Corporate Overview October 2025 Nasdaq: OBIO ──────────────── Forward-Looking Statements This presentation has been prepared for informational purposes only from information supplied by Orchestra BioMed Holdings, Inc., referred to herein as “we,” “our,” “Orchestra BioMed,” and “the Company,” and from third-party sources indicated herein. Such third-party information has not been independently…
Read attachment ↗